Panama7/iStock Editorial via Getty Images
- On Monday, Sanofi (NASDAQ:SNY) and partner Regeneron (NASDAQ:REGN) announced positive topline data from a late-stage trial for Dupixent (dupilumab) in patients aged 12 years and above with eosinophilic esophagitis ((EoE)).
Commenting on the results, Bank of America analysts led by Graham Parry project a EUR 1.1B sales opportunity in EoE for Dupixent, a human monoclonal antibody already approved by the FDA for several inflammatory conditions, including atopic dermatitis.
- However, arguing that the positive readout was anticipated given the favorable results from a previous mid-stage trial, the analysts reiterate the Buy rating, which is based on the undervalued growth. The price target of USD 69.00 implies a premium of ~38.2% to the last close.
- Parry and the team consider EoE as one of several new indications that could propel Dupixent to generate peak sales of EUR 16.5B on an unadjusted basis compared to EUR 11.7B in the consensus.
- Just last week, the two companies shared positive data for Dupixent from a late-stage trial in patients with an inflammatory skin disease called prurigo nodularis.